Table 2.
Discounted base case results
| Technologies | Total | Incremental | ICER (£) | ||||
|---|---|---|---|---|---|---|---|
| Add-on to MET | Costs (£) | LYs | QALYs | Costs (£) | LYs | QALYs | Incremental cost per QALY gained |
| DPP-4i | £13,593 | 14.80 | 11.83 | - | - | - | - |
| Dapagliflozin | £13,809 | 14.80 | 11.86 | +£216 | 0.01 | +0.032 | £6,761 |
Abbreviations: LYs, life years; QALYs, quality-adjusted life years; ICER incremental cost-effectiveness ratio